N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide
C19H31N5O3 — CID 155913923
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide
N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide (PubChem CID 155913923) has the molecular formula C19H31N5O3 and a molecular weight of 377.49 g/mol. Its IUPAC name is N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide.
Molecular Properties
| Compound Name | N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide |
|---|---|
| PubChem CID | 155913923 |
| Molecular Formula | C19H31N5O3 |
| Molecular Weight | 377.49 g/mol |
| Exact Mass | 377.24 |
| IUPAC Name | N-[(1R,2R,4S)-2-hydroxy-4-(2-pyrrolidin-1-ylethylcarbamoyl)cyclopentyl]-2,4,5-trimethylpyrazole-3-carboxamide |
| SMILES | Cc1nn(C)c(C(=O)N[C@@H]2C[C@H](C(=O)NCCN3CCCC3)C[C@H]2O)c1C |
| InChI | InChI=1S/C19H31N5O3/c1-12-13(2)22-23(3)17(12)19(27)21-15-10-14(11-16(15)25)18(26)20-6-9-24-7-4-5-8-24/h14-16,25H,4-11H2,1-3H3,(H,20,26)(H,21,27)/t14-,15+,16+/m0/s1 |
| InChIKey | HWIBMZCWWOPAPH-ARFHVFGLSA-N |
| XLogP | 0.12 |
| TPSA | 99.49 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 377.49 |
| LogP ≤ 5 | 0.12 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155913923 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.